"We are encouraged by the emerging safety profile and initial signals of anti-tumor activity of COM701," said Compugen president and CEO Dr. Anat Cohen-Dayan.
READ ARTICLE by Eytan Halon. Published by The Jerusalem Post, November 5, 2019.
top of page
bottom of page
Comments